QIAGEN N.V.
QGEN Healthcare Diagnostics & Research
QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 7.94%, free cash flow grew 30.5% and total debt rose 13.8%, each against the same quarter a year earlier.
Follow QGEN
QIAGEN N.V. (QGEN) EV/Sales
As of 16 October 2026, QIAGEN N.V. (QGEN) trades at a EV/Sales of 4.9×. Over the past ten years it has ranged from 3.9× (May 2026) to 7.4× (August 2020); the current reading is higher than 35% of that period. That is below the Diagnostics & Research industry median of 5.5× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.2× | 0.91% |
| FY2024 | 5.1× | (1.28%) |
| FY2023 | 5.2× | (1.26%) |
| FY2022 | 5.3× | (5.86%) |
| FY2021 | 5.6× | (15.44%) |
| FY2020 | 6.6× | 27.36% |
| FY2019 | 5.2× | (1.24%) |
| FY2018 | 5.3× | 1.45% |
| FY2017 | 5.2× | 0.45% |
| FY2016 | 5.2× | (3.28%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.2× | (8.95%) |
| Mar 2026 | 4.7× | (9.94%) |
| Dec 2025 | 5.2× | 11.21% |
| Sep 2025 | 4.7× | (12.89%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ICLR ICON PLC compare | 1.9× |
| RDNT RadNet, Inc. compare | 2.6× |
| CRL Charles River Laboratories International, Inc. compare | 4.2× |
| QGEN QIAGEN N.V. | 4.9× |
| SHC Sotera Health Company compare | 5.7× |
| MEDP Medpace Holdings, Inc. compare | 6.1× |
| RVTY Revvity Inc. compare | 6.6× |
| TWST Twist Bioscience Corporation compare | 18.8× |
| GRAL GRAIL, Inc. compare | 25.5× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)